Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:46 PM
Ignite Modification Date:
2025-12-24 @ 7:46 PM
NCT ID:
NCT06943703
Eligibility Criteria:
Inclusion Criteria:
* Age: Pediatric patients under the age of 18 years.
* Diagnosis: Confirmed diagnosis of lymphangioma (lymphatic malformation).
* Location of Lesions: Lymphangiomas located in the head and neck, axilla, abdomen, thorax, groin, or extremities.
* Treatment History: No prior treatment with Bleomycin for lymphangioma.
* Health Status: No serious comorbidities or medical conditions that could interfere with the study or treatment process.
* Informed Consent: Patients (or their legal guardians) provide informed consent to participate in the study.
Exclusion Criteria:
* Age: Patients over the age of 18 years.
* Pregnancy: Pregnant or breastfeeding patients.
* Other Treatments: Patients who have received prior treatments with Bleomycin for lymphangioma.
* Severe Comorbidities: Presence of serious comorbidities (e.g., uncontrolled cardiovascular disease, active infections) that may interfere with the study or treatment process.
* Allergy: Known allergy or hypersensitivity to Bleomycin or any of its components.
* Active Infections: Patients with active local or systemic infections at the time of enrollment.
* Immunosuppression: Immunocompromised patients (due to illness or medications).
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
18 Years
Study:
NCT06943703
Study Brief:
Protocol Section:
NCT06943703